Tango Therapeutics Inc. (TNGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics stock soars on promising pancreatic cancer data
Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat. The drug was tested in combination with Revolution Medicines' daraxonrasib.
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.
Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX
Avoro Capital Advisors LLC acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 545,000 shares of the company's stock, valued at approximately $4,578,000. Avoro Capital Advisors LLC owned approximately
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise
Tango Therapeutics, Inc. is downgraded to Hold after a sharp rally, with 2026 positioned as a pivotal, data-driven year. Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition.
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy
Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications.
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago.
